Hepatitis C virus (HCV) is the leading cause of liver fibrosis and hepatocellular carcinoma (HCC). At present, there is no predictive biomarker for the patients at high risk of developing HCC. In this study, we examined the association between single-nucleotide polymorphisms (SNPs) in 3 innate immunity genes [2′-5′oligoadenylate synthetase 1 (OAS1) rs10774671, interleukin 28B (IL28B) rs12979860, and low molecular mass polypeptide 7 (LMP-7) at codon 49] besides cytomegalovirus (CMV) coinfection and susceptibility to HCC in genotype 4 (GT4) chronically infected Egyptian patients. SNPs were determined using restriction fragment length polymorphism analysis in DNA from HCC patients (n = 34) and compared with either controls (n = 70) or patients with early grades of liver fibrosis (n = 49). Our results demonstrated that patients bearing the genetic combination consisting of LMP-7 CA/AA [OR 4.75, 95% confidence interval (CI) 1.443–15.631, P = 0.007] and IL28B rs12979860 CT/TT (OR 6.00, 95% CI 1.603–22.455, P = 0.004) and positive for CMV viremia (OR 3.11, 95% CI 1.151–8.412, P = 0.02) were more likely to have HCC. However, OAS1 rs10774671 does not seem to contribute to the development of HCC. Binary regression analysis indicated that HCC risk significantly increases with the presence of each unfavorable genotype (LMP-7 CA/AA, IL28B rs12979860 CT/TT), when accompanied by the existence of CMV coinfection (probability of HCC risk is 0.8 for combined factors versus 0.14, 0.07, and 0.07 for individual factor IL28B, LMP-7, and CMV; respectively). These data suggest that the 2 SNPs and the coinfection in concert have potential in predicting the risk of HCC development in patients infected with HCV GT4.
Get full access to this article
View all access options for this article.
References
1.
AkkizH, KuranS, AkgolluE, UskudarO, BekarA, BayramS. 2014. The role of interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Ann Hepatol, 13(6):788–795.
2.
AndradeL, MeloR, SouzaE, SilvaC, ParanaR. 2009. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis, 1(1):5.
3.
Bader el-DinNG, Abd el-MeguidM, TabllAA, AnanyMA, EsmatG, ZayedN, HelmyA, el-ZayadyAR, BarakatA, el-AwadyMK. 2011. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol, 26(1):55–62.
4.
Bader El DinNG, AnanyMA, DawoodRM, IbrahimMK, El-ShenawyR, El AbdYS, El AwadyMK. 2015. Impact of OAS1 exon 7 rs10774671 genetic variation on liver fibrosis progression in Egyptian HCV genotype 4 patients. Viral Immunol, 28(9):509–516.
5.
BayramA, OzkurA, ErkilicS. 2009. Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects. J Clin Virol, 45(3):212–217.
6.
CaoB, TianX, LiY, JiangP, NingT, XingH, ZhaoY, ZhangC, ShiX, ChenD, ShenY, KeY. 2005. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis, 26(7):1280–1284.
7.
ChangKC, TsengPL, WuYY, HungHC, HuangCM, LuSN, WangJH, LeeCM, ChenCH, TsaiMC, YenYH, LinMT, WuCK, HuangCC, ChenHH, HuTH. 2015. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol, 13(5):1017–1024.
8.
ChopraKB, DemetrisAJ, BlakolmerK, DvorchikI, LaskusT, WangLF, ArayaVR, DodsonF, FungJJ, RakelaJ, VargasHE. 2003. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation, 76(10):1487–1491.
9.
CuiQ, ZhangY, SuJ, ShiC, LeiN, DingK, LiJ, YuR, WangL, WangN. 2010. The association between the genetic polymorphisms of LMP2/LMP7 and the outcomes of HCV infection among drug users. J Biomed Res, 24(5):374–380.
10.
de VeerMJ, HolkoM, FrevelM, WalkerE, DerS, ParanjapeJM, SilvermanRH, WilliamsBR. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol, 69(6):912–920.
11.
El-AwadyMK, MostafaL, TabllAA, AbdelhafezTH, Bader El DinNG, ZayedN, ShenawyRE, El AbdY, HasanRM, ZaghlolH, El KhayatH, Abdel AzizAO. 2012. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon, 12(4):271–277.
12.
El AwadyMK, AnanyMA, EsmatG, ZayedN, TabllAA, HelmyA, El ZayadyAR, AbdallaMS, SharadaHM, El RazikyM, El AkelW, AbdallaS, Bader El DinNG. 2011. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol, 26(5):843–850.
13.
FellerhoffB, GuS, LaumbacherB, NerlichAG, WeissEH, GlasJ, KoppR, JohnsonJP, WankR. 2011. The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Res, 71(23):7145–7154.
14.
FoxJD, BrinkNS, ZuckermanMA, NeildP, GazzardBG, TedderRS, MillerRF. 1995. Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis, 172(4):1087–1090.
15.
FrenchBA, OlivaJ, Bardag-GorceF, FrenchSW. 2011. The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Exp Mol Pathol, 90(3):252–256.
GobelT, VorderwulbeckeS, HauckK, FeyH, HaussingerD, ErhardtA. 2006. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol, 12(47):7604–7612.
ImranM, ManzoorS, KhattakNM, TariqM, KhalidM, JavedF, BhattiS. 2014. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. Viral Immunol, 27(3):105–111.
20.
IshidaC, IkebuchiY, OkamotoK, MurawakiY. 2011. Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection. Intern Med, 50(7):659–666.
21.
JonesRN, NealeML, BeattieB, WestmorelandD, FoxJD. 2000. Development and application of a PCR-based method including an internal control for diagnosis of congenital cytomegalovirus infection. J Clin Microbiol, 38(1):1–6.
22.
KozielMJ. 1999. Cytokines in viral hepatitis. Semin Liver Dis, 19(2):157–169.
23.
LiT, FanJ, QinLX, ZhouJ, SunHC, QiuSJ, YeQH, WangL, TangZY. 2011. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol, 18(7):1955–1963.
24.
LiuL, YanM, ZhangXH, ZhuP, ZhangL. 2008. [An experimental study on the relationship between proteasome LMP7 subunit and alcoholic liver disease]. Zhonghua Gan Zang Bing Za Zhi, 16(11):827–830.
25.
MaJ, LiuYC, FangY, CaoY, LiuZL. 2015. TGF-beta1 polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. Genet Mol Res, 14(2):4461–4468.
26.
McCaughanGW, GeorgeJ. 2004. Fibrosis progression in chronic hepatitis C virus infection. Gut, 53(3):318–321.
27.
Mohd HanafiahK, GroegerJ, FlaxmanAD, WiersmaST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57(4):1333–1342.
28.
OmranMH, FotouhBE, YoussefSS, IbrahimNE, NabilW, Mahdy elSM, ShoshaWG, El-AwadyMK. 2013. Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection. World J Hepatol, 5(3):97–103.
29.
ParA, ParG, TornaiI, SzalayF, VarszegiD, FraterE, PappM, LengyelG, FeherJ, VargaM, GervainJ, SchullerJ, NemesZ, PeterfiZ, TusnadiA, HunyadyB, HaraghA, SzinkuZ, VinczeA, SzeredayL, KisfaliP, MeleghB. 2014. IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes, 7:12.
30.
ParkJS, NeerajS, DieterichDT. 2005. Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV. Curr Hepat Rep, 4(2):4.
31.
RauchA, KutalikZ, DescombesP, CaiT, Di IulioJ, MuellerT, BochudM, BattegayM, BernasconiE, BorovickaJ, ColomboS, CernyA, DufourJF, FurrerH, GunthardHF, HeimM, HirschelB, MalinverniR, MoradpourD, MullhauptB, WitteckA, BeckmannJS, BergT, BergmannS, NegroF, TelentiA, BochudPY. 2010a. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4):1338–1345, 1345 e1–e7.
32.
RauchA, RohrbachJ, BochudPY. 2010b. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest, 40(10):950–959.
33.
RazonableRR, BurakKW, van CruijsenH, BrownRA, CharltonMR, SmithTF, EspyMJ, KremersW, WilsonJA, GroettumC, WiesnerR, PayaCV. 2002. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis, 35(8):974–981.
34.
RosenHR, ChouS, CorlessCL, GretchDR, FloraKD, BoudousquieA, OrloffSL, RabkinJM, BennerKG. 1997. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation, 64(5):721–726.
35.
SebastianiG, AlbertiA. 2006. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol, 12(23):3682–3694.
36.
SongL, MaN, HanL, YanH, YanB, YuanZ, CaoB. 2014. Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing. Hum Immunol, 75(3):239–244.
37.
StarkGR. 2007. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev, 18(5–6):419–423.
38.
TanakaY, NishidaN, SugiyamaM, KurosakiM, MatsuuraK, SakamotoN, NakagawaM, KorenagaM, HinoK, HigeS, ItoY, MitaE, TanakaE, MochidaS, MurawakiY, HondaM, SakaiA, HiasaY, NishiguchiS, KoikeA, SakaidaI, ImamuraM, ItoK, YanoK, MasakiN, SugauchiF, IzumiN, TokunagaK, MizokamiM. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 41(10):1105–1109.
39.
ThomasDL, ThioCL, MartinMP, QiY, GeD, O'HuiginC, KiddJ, KiddK, KhakooSI, AlexanderG, GoedertJJ, KirkGD, DonfieldSM, RosenHR, ToblerLH, BuschMP, McHutchisonJG, GoldsteinDB, CarringtonM. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461(7265):798–801.
40.
ThompsonA, PatelK, TillmanH, McHutchisonJG. 2009. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol, 50(1):184–194.
41.
TolmaneI, RozentaleB, KeissJ, IvancenkoL, SubnikovaN, ReinholdeZ, KozlovskaI, SumlaninovaN, LaivacumaS, SimanisR. 2012. Interleukin 28B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat Res Treat, 2012:324090.
42.
TrowsdaleJ, HansonI, MockridgeI, BeckS, TownsendA, KellyA. 1990. Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters. Nature, 348(6303):741–744.
43.
Vargas-AlarconG, GamboaR, ZunigaJ, FragosoJM, Hernandez-PachecoG, LondonoJ, Pacheco-TenaC, CardielMH, GranadosJ, Burgos-VargasR. 2004. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Hum Immunol, 65(12):1437–1442.
44.
WHO. 2014. Hepatitis C, WHO fact sheet No. 164, updated April. Available at www.who.int/mediacentre/factsheets/fs164/en
45.
YorkIA, RockKL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol, 14:369–396.
46.
ZekriAR, SalamaH, MedhatE, BahnassyAA, MorsyHM, LotfyMM, AhmedR, DarwishT, MareiMS. 2014. IL28B rs12979860 gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev, 15(17):7213–7218.
